{"id":"placebo-part-i","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1201595","moleculeType":"Enzyme"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo Part I","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:49:22.869147+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:49:38.341758+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:49:30.313773+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo Part I","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:49:30.912619+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dermatan sulfate hydrolytic enzyme","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:49:32.408289+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201595/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:49:32.057046+00:00"}},"_dailymed":null,"aiSummary":"Placebo Part I, marketed by Orion Corporation, Orion Pharma, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not provided. The primary risk is the potential increase in competition following the patent expiry in 2028.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is a non-active substance administered in clinical trials to establish baseline efficacy and safety profiles of investigational drugs through comparison. It leverages the placebo effect—the therapeutic benefit arising from patient expectation and clinical context rather than the drug's inherent pharmacological properties. Placebos are essential for blinded, controlled trial designs to isolate true drug effects from psychological and environmental factors.","oneSentence":"Placebo produces no pharmacological effect and serves as an inert control or reference standard in clinical research.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:42:07.284Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:49:38.341827+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Clinical trial control / comparator (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT07495813","phase":"PHASE1","title":"A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Stable Coronary Artery Disease, Healthy Volunteers","enrollment":196},{"nctId":"NCT06714253","phase":"PHASE1, PHASE2","title":"Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1","status":"RECRUITING","sponsor":"RiboX Therapeutics Ltd.","startDate":"2025-03-05","conditions":"Radiation-Induced Xerostomia and Hyposalivation","enrollment":42},{"nctId":"NCT06980428","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-27","conditions":"Healthy Participants, Dyslipidemia","enrollment":136},{"nctId":"NCT07290283","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-10","conditions":"Healthy Participants","enrollment":176},{"nctId":"NCT07493031","phase":"PHASE1","title":"A PhaseⅠ Study of HW252001 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","startDate":"2026-03-31","conditions":"IPF","enrollment":98},{"nctId":"NCT07489599","phase":"PHASE1","title":"A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)","enrollment":68},{"nctId":"NCT07024823","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-09","conditions":"Chronic Kidney Disease","enrollment":124},{"nctId":"NCT07310264","phase":"PHASE1","title":"Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease","status":"RECRUITING","sponsor":"Vertero Therapeutics","startDate":"2025-10-30","conditions":"Healthy Volunteers (HV), Parkinson's Disease (PD)","enrollment":84},{"nctId":"NCT06995820","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-06","conditions":"Healthy","enrollment":136},{"nctId":"NCT07392372","phase":"PHASE1","title":"A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-09","conditions":"HIV -1 Infection","enrollment":61},{"nctId":"NCT05440643","phase":"PHASE1, PHASE2","title":"Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ALK-Abelló A/S","startDate":"2022-09-07","conditions":"Peanut Allergy","enrollment":192},{"nctId":"NCT05406362","phase":"PHASE1, PHASE2","title":"Assess Safety and Efficacy of VAD044 in HHT Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaderis Therapeutics AG","startDate":"2022-07-18","conditions":"Hereditary Hemorrhagic Telangiectasia (HHT)","enrollment":75},{"nctId":"NCT05396105","phase":"PHASE2, PHASE3","title":"Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","status":"ENROLLING_BY_INVITATION","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-12-28","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":150},{"nctId":"NCT05476497","phase":"PHASE1","title":"Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Allergy Therapeutics","startDate":"2022-10-17","conditions":"Peanut Allergy","enrollment":46},{"nctId":"NCT07228364","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-10","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":40},{"nctId":"NCT06166056","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-29","conditions":"Bronchiectasis","enrollment":45},{"nctId":"NCT07223216","phase":"PHASE1","title":"Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants","status":"RECRUITING","sponsor":"Biomea Fusion Inc.","startDate":"2025-10-23","conditions":"Obesity","enrollment":80},{"nctId":"NCT07090785","phase":"PHASE1","title":"A Study of LY4088044 in Healthy Participants","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-07-24","conditions":"Healthy","enrollment":104},{"nctId":"NCT06306014","phase":"PHASE1, PHASE2","title":"Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-05-07","conditions":"Clostridioides Difficile Infection, Recurrent Infection","enrollment":56},{"nctId":"NCT07047703","phase":"PHASE1, PHASE2","title":"EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)","status":"RECRUITING","sponsor":"Grey Wolf Therapeutics","startDate":"2025-07-28","conditions":"Axial Spondyloarthritis (AxSpA)","enrollment":141},{"nctId":"NCT07246941","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-11-19","conditions":"Huntington's Disease","enrollment":40},{"nctId":"NCT05469737","phase":"PHASE2, PHASE3","title":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes","enrollment":230},{"nctId":"NCT07429565","phase":"PHASE1","title":"Testing APPA-1 in Healthy Subjects and Osteoarthritis Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2018-04-09","conditions":"Osteoarthritis","enrollment":40},{"nctId":"NCT06650761","phase":"PHASE1","title":"A Phase I Study of CDX-622","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-11-01","conditions":"Healthy Participants","enrollment":85},{"nctId":"NCT06515002","phase":"PHASE1, PHASE2","title":"A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2024-11-04","conditions":"Cystic Fibrosis","enrollment":5},{"nctId":"NCT06716905","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2025-03-06","conditions":"Non-alcoholic Steatohepatitis","enrollment":72},{"nctId":"NCT03157635","phase":"PHASE1, PHASE2","title":"Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-11-14","conditions":"Paroxysmal Hemoglobinuria, Nocturnal","enrollment":59},{"nctId":"NCT07356271","phase":"EARLY_PHASE1","title":"Effects of Mouthwashes on the Oral Microbiome and Systemic Health","status":"NOT_YET_RECRUITING","sponsor":"University of Plymouth","startDate":"2026-02-01","conditions":"Hypertension","enrollment":200},{"nctId":"NCT06106828","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-11-15","conditions":"Thyroid Eye Disease","enrollment":127},{"nctId":"NCT07403604","phase":"PHASE1","title":"Effect of Insulin Lowering on Lipogenesis","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-04","conditions":"Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease","enrollment":25},{"nctId":"NCT07282613","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-04","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT05987423","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-26","conditions":"Thyroid Eye Disease, TED","enrollment":131},{"nctId":"NCT06546670","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-08-15","conditions":"Sickle Cell Disease","enrollment":161},{"nctId":"NCT06888362","phase":"PHASE1","title":"Trial to Investigate GZ21T in Healthy Volunteers","status":"COMPLETED","sponsor":"Genzada Pharmaceuticals USA, Inc.","startDate":"2024-08-19","conditions":"Actinic Keratosis","enrollment":41},{"nctId":"NCT06103877","phase":"PHASE1","title":"A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-01","conditions":"Healthy Volunteers","enrollment":108},{"nctId":"NCT06265532","phase":"PHASE1","title":"Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hal Chapman","startDate":"2024-02-07","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":22},{"nctId":"NCT06381466","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-04-01","conditions":"Dilated Cardiomyopathy","enrollment":84},{"nctId":"NCT06238466","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-01-16","conditions":"Cardiovascular","enrollment":96},{"nctId":"NCT04588428","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2021-06-21","conditions":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","enrollment":192},{"nctId":"NCT06151964","phase":"PHASE1, PHASE2","title":"A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-29","conditions":"Overweight and Obesity","enrollment":118},{"nctId":"NCT06493084","phase":"PHASE1","title":"Evaluate LAE102 in Healthy and Overweight/Obese Subjects","status":"RECRUITING","sponsor":"Laekna Limited","startDate":"2024-06-25","conditions":"Overweight and Obese Volunteers","enrollment":160},{"nctId":"NCT05576012","phase":"PHASE1","title":"First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts","status":"COMPLETED","sponsor":"Lipum AB","startDate":"2022-10-13","conditions":"Rheumatoid Arthritis","enrollment":56},{"nctId":"NCT04481750","phase":"PHASE1","title":"Study of Oral Edaravone in Healthy Adult Males","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-03-20","conditions":"Healthy Adult Subjects","enrollment":74},{"nctId":"NCT07318883","phase":"PHASE2, PHASE3","title":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-03","conditions":"Squamous NSCLC","enrollment":720},{"nctId":"NCT07172646","phase":"PHASE1, PHASE2","title":"A Study of SRSD216 in Patients With Elevated Lipoprotein (a)","status":"RECRUITING","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2025-04-07","conditions":"Hyperlipoproteinemia (a)","enrollment":84},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT06181370","phase":"PHASE1","title":"Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF","status":"RECRUITING","sponsor":"Agomab Spain S.L.","startDate":"2023-12-01","conditions":"IPF","enrollment":145},{"nctId":"NCT06504290","phase":"PHASE1","title":"Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119","status":"RECRUITING","sponsor":"Vigonvita Life Sciences","startDate":"2024-07-16","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT04939597","phase":"PHASE3","title":"A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-05-10","conditions":"Central Nervous System Carcinoma","enrollment":192},{"nctId":"NCT06877364","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Efficacy of GcMAF in Patients With Chronic Inflammatory Diseases","status":"COMPLETED","sponsor":"S.LAB (SOLOWAYS)","startDate":"2025-09-01","conditions":"Inflammation","enrollment":120},{"nctId":"NCT07118085","phase":"PHASE1","title":"A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women","status":"RECRUITING","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2025-08-18","conditions":"Healthy Postmenopausal Women","enrollment":56},{"nctId":"NCT06502379","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-02","conditions":"Healthy Participants","enrollment":147},{"nctId":"NCT06354088","phase":"PHASE1","title":"Human Models of Selective Insulin Resistance: Alpelisib, Part I","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-04-24","conditions":"Insulin Resistance, Prediabetic State, Overweight and Obesity","enrollment":32},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT06905327","phase":"PHASE1","title":"A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-08","conditions":"Mild Hypertension","enrollment":56},{"nctId":"NCT07237425","phase":"PHASE1","title":"Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma","status":"RECRUITING","sponsor":"Glonova Pharma Co., Ltd","startDate":"2025-11-14","conditions":"Lipoma, Submental Fullness","enrollment":56},{"nctId":"NCT07259538","phase":"PHASE1","title":"A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray","status":"RECRUITING","sponsor":"VivaVision Biotech, Inc","startDate":"2025-11-06","conditions":"Chronic Rhinosinusitis (CRS)","enrollment":60},{"nctId":"NCT03687957","phase":"PHASE1, PHASE2","title":"rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-01-04","conditions":"Glioma","enrollment":42},{"nctId":"NCT07038720","phase":"PHASE1","title":"A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Usynova Pharmaceuticals Ltd.","startDate":"2025-05-08","conditions":"Plaque Psoriasis, Healthy Volunteer","enrollment":124},{"nctId":"NCT05547503","phase":"PHASE1","title":"Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers","status":"COMPLETED","sponsor":"Afasci Inc","startDate":"2023-04-11","conditions":"Pain, Neuropathic, Pain, Inflammatory","enrollment":64},{"nctId":"NCT05432583","phase":"PHASE1","title":"A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2022-12-08","conditions":"Genital Herpes Simplex Type 2","enrollment":318},{"nctId":"NCT06776432","phase":"PHASE2","title":"Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea","status":"RECRUITING","sponsor":"Shionogi Apnimed Sleep Science","startDate":"2025-04-02","conditions":"Sleep Apnea","enrollment":60},{"nctId":"NCT06508021","phase":"PHASE2, PHASE3","title":"A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ashibio Inc","startDate":"2024-10-25","conditions":"Fibrodysplasia Ossificans Progressiva","enrollment":92},{"nctId":"NCT07199946","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil","status":"RECRUITING","sponsor":"Johnny Ludvigsson","startDate":"2025-08-06","conditions":"Type 1 Diabetes","enrollment":36},{"nctId":"NCT04643457","phase":"PHASE1, PHASE2","title":"A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2020-11-27","conditions":"Atopic Dermatitis","enrollment":107},{"nctId":"NCT06115993","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2023-08-03","conditions":"Hepatitis B, Chronic","enrollment":129},{"nctId":"NCT05183360","phase":"PHASE1","title":"A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2022-02-07","conditions":"Healthy","enrollment":48},{"nctId":"NCT06705998","phase":"PHASE1","title":"To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects","status":"RECRUITING","sponsor":"BAR Pharmaceuticals s.r.l.","startDate":"2024-12-04","conditions":"NASH","enrollment":52},{"nctId":"NCT03971695","phase":"PHASE1","title":"A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-06-18","conditions":"Healthy","enrollment":73},{"nctId":"NCT07178327","phase":"PHASE1","title":"Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai TTM-Bio Technology Co., Ltd","startDate":"2025-09-06","conditions":"Osteoporotic Fracture","enrollment":44},{"nctId":"NCT05844735","phase":"PHASE1","title":"A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-05-22","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT06022354","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2023-08-23","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT06138795","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-20","conditions":"Healthy Participants","enrollment":120},{"nctId":"NCT05298254","phase":"PHASE1, PHASE2","title":"A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-07","conditions":"Herpes Simplex","enrollment":505},{"nctId":"NCT07152444","phase":"PHASE1","title":"A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09","conditions":"Uncontrolled Hypertension","enrollment":78},{"nctId":"NCT06999720","phase":"PHASE1","title":"Study of HX15001 in Adult Healthy Volunteers.","status":"RECRUITING","sponsor":"Helixon Biotechnology (Suzhou) Co., Ltd","startDate":"2025-06-11","conditions":"Healthy Volunteers","enrollment":62},{"nctId":"NCT06133270","phase":"PHASE1","title":"A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-11-13","conditions":"Healthy Volunteers - Liver Diseases","enrollment":51},{"nctId":"NCT06469164","phase":"PHASE1","title":"A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2024-07-01","conditions":"Bacterial Vaginosis","enrollment":102},{"nctId":"NCT06659757","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects","status":"COMPLETED","sponsor":"Kither Biotech Srl","startDate":"2024-10-16","conditions":"Cystic Fibrosis","enrollment":56},{"nctId":"NCT07098117","phase":"PHASE1","title":"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetic Profile of Single and Multiple Dose Escalation Topical Dermal Administration of SHR0302 Alkali Gel in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-06-19","conditions":"Preoperative Sedation of Adults","enrollment":32},{"nctId":"NCT06946641","phase":"PHASE1","title":"A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients","status":"RECRUITING","sponsor":"Shanghai Qilu Pharmaceutical Research and Development Center LTD","startDate":"2025-03-31","conditions":"Atopic Dermatitis, Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA)","enrollment":102},{"nctId":"NCT05047185","phase":"PHASE2","title":"Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II","status":"COMPLETED","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-04-19","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":34},{"nctId":"NCT06637865","phase":"PHASE1","title":"A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers","status":"RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2024-07-17","conditions":"Healthy","enrollment":79},{"nctId":"NCT06891625","phase":"NA","title":"Movement Performance in Persons With Chronic Back Pain","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-09-01","conditions":"Chronic Low-back Pain, Back Disorder","enrollment":40},{"nctId":"NCT06491550","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-07-15","conditions":"Healthy Participants","enrollment":91},{"nctId":"NCT07044960","phase":"PHASE1","title":"A Phase 1 Study of KHN702 Tablets in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2025-06-21","conditions":"Healthy","enrollment":84},{"nctId":"NCT07041801","phase":"PHASE1, PHASE2","title":"Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells","status":"RECRUITING","sponsor":"Shenzhen Beike Bio-Technology Co., Ltd.","startDate":"2025-06-28","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":58},{"nctId":"NCT07017114","phase":"PHASE1","title":"Pentoxifylline PKB171 Gel in Healthy Females Volunteers","status":"COMPLETED","sponsor":"Prokrea BCN, S.L.","startDate":"2016-01-27","conditions":"Safety, Pharmacokinetics, Maximum Tolerated Dose","enrollment":30},{"nctId":"NCT06105151","phase":"PHASE1","title":"Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers","status":"RECRUITING","sponsor":"Vigonvita Life Sciences","startDate":"2023-10-27","conditions":"Schizophrenia","enrollment":82},{"nctId":"NCT07001787","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-06","conditions":"Dyslipidemia","enrollment":88},{"nctId":"NCT00529113","phase":"PHASE1","title":"Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Biogen","startDate":"2007-09-30","conditions":"Pancreatic Neoplasms, Pancreatic Cancer","enrollment":33},{"nctId":"NCT04473690","phase":"PHASE1, PHASE2","title":"KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","status":"COMPLETED","sponsor":"KBio Inc","startDate":"2020-12-30","conditions":"Covid19","enrollment":102},{"nctId":"NCT03835117","phase":"PHASE2","title":"Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Rossignol Medical Center","startDate":"2020-02-01","conditions":"Autism Spectrum Disorder","enrollment":16},{"nctId":"NCT05979428","phase":"PHASE1","title":"A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-08-07","conditions":"Healthy Volunteers, Dyslipidaemia","enrollment":106},{"nctId":"NCT04208412","phase":"PHASE2","title":"A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II","status":"COMPLETED","sponsor":"KalVista Pharmaceuticals, Ltd.","startDate":"2019-07-02","conditions":"Hereditary Angioedema","enrollment":84},{"nctId":"NCT04313400","phase":"PHASE1, PHASE2","title":"Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Amytrx Therapeutics, Inc.","startDate":"2020-03-10","conditions":"Atopic Dermatitis","enrollment":91},{"nctId":"NCT06951880","phase":"PHASE1","title":"A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-27","conditions":"Healthy Participants","enrollment":178},{"nctId":"NCT06048588","phase":"PHASE1, PHASE2","title":"YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis","status":"COMPLETED","sponsor":"Beijing Inno Medicine Co., Ltd.","startDate":"2023-10-08","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":144},{"nctId":"NCT04163562","phase":"PHASE1, PHASE2","title":"Oral Immunotherapy for Peanut Allergic Patients","status":"RECRUITING","sponsor":"InnoUp Farma S.L.","startDate":"2020-03-11","conditions":"Peanut Allergy","enrollment":50},{"nctId":"NCT06441227","phase":"PHASE1","title":"Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-06-13","conditions":"Lipoprotein Disorder Disease","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1201595"},"_approvalHistory":[],"publicationCount":212,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["iron sucrose injection - Venofer","RCN3028 placebo","Saline","Machkhan Tab. 8/5 mg(or Machkhan Tab. 16/5 mg)"],"phase":"marketed","status":"active","brandName":"Placebo Part I","genericName":"Placebo Part I","companyName":"Orion Corporation, Orion Pharma","companyId":"orion-corporation-orion-pharma","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:49:38.341827+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}